Articles - GLP1 drugs changing weight loss and Life & Health insurance


Weight-loss injectables like Wegovy or Ozempic are gaining popularity amid an escalating global obesity crisis. Since 1975, worldwide obesity rates have nearly tripled, with projections indicating that over half of the global population will be overweight or obese by 2035. John Schoonbee, Global Chief Medical Officer, and Adam Strange, Life & Health R&D Manager, elaborate on the impact of GLP-1 drugs on weight loss, metabolic health and insurance. These medications influence risk factors such as insulin resistance, cardiovascular disease, and cancer. Additionally, they discuss the implications of these drugs on Life & Health insurance, including life, critical illness, and disability income, as well as future underwriting risk assessments.

 

Back to Index


Similar News to this Story

Creakonomics all it would take is a push
The concept of “financially material” risks, and whether you can take actions to deal with them, has never been more relevant. That makes your life
Equity. When you’ve got FX and you want it hedged its equity
FX hedging is a perennial question, in part because it’s often difficult to answer and the evidence is ambiguous. For lower risk assets, it makes sens
Cutting through the noise on surpluses in the LGPS
There has been a lot of buzz lately about surpluses in the LGPS. You might have heard stories about billions of unused pounds trapped in the various p

Site Search

Exact   Any  

Latest Actuarial Jobs

Actuarial Login

Email
Password
 Jobseeker    Client
Reminder Logon

APA Sponsors

Actuarial Jobs & News Feeds

Jobs RSS News RSS

WikiActuary

Be the first to contribute to our definitive actuarial reference forum. Built by actuaries for actuaries.